Crinetics Pharmaceuticals, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.

Symbol
CRNX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
26 Feb 2026

Quick Takeaways

  • CRNX - Crinetics Pharmaceuticals, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q4 2025.
  • Headline metric: Return On Equity -40%.

What Changed

  • Return On Equity YoY change: <span class="text-green-600">+25%</span>.
  • Most recent SEC facts end date: 13 Feb 2026.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2026-02-13) highlights Return On Equity -40.2%, Return On Assets -36.3%, and Operating Margin -6714.8%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

28.7/100

Weak Confidence high

Return On Equity

-40%

Metric score 0.0/100

Return On Assets

-36%

Metric score 0.0/100

Financial Health

Current Ratio
12.32x
Quick Ratio
11.76x
Debt to Equity
0.11x

Strengths

Debt-to-equity and Revenues YoY

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-40%

YoY: +25%

Industry median: -43% (n=675)

View history

Return On Assets

-36%

YoY: +26%

Industry median: -47% (n=673)

View history

Operating Margin

-6715%

YoY: -79%

Industry median: -121% (n=298)

View history

Current Ratio

12.32x

YoY: -47%

Industry median: 3.39x (n=667)

View history

Quick Ratio

11.76x

YoY: -50%

Industry median: 1.51x (n=289)

View history

Debt-to-equity

0.11x

YoY: -1.5%

Industry median: 0.26x (n=530)

View history

Revenues YoY

641%

YoY:

Industry median: 7.3% (n=302)

View history

NetIncomeLoss YoY

-56%

YoY:

Industry median: -0.93% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity -40% +25%
Return On Assets -36% +26%
Operating Margin -6715% -79%

Financial Health

Metric Latest value YoY change
Current Ratio 12.32x -47%
Quick Ratio 11.76x -50%
Debt-to-equity 0.11x -1.5%

Growth

Metric Latest value YoY change
Revenues YoY 641%
NetIncomeLoss YoY -56%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 104,705,330
Common Stock, Shares, Outstanding 95,575,000 +2.9%
Weighted Average Number of Shares Outstanding, Basic 94,057,000 +16%
Weighted Average Number of Shares Outstanding, Diluted 94,057,000 +16%

Additional Metrics

Metric Latest value YoY change
Revenue from Contract with Customer, Excluding Assessed Tax $7,696,000 +641%
Research and Development Expense $332,058,000 +38%
Operating Income (Loss) $516,769,000 -53%
Nonoperating Income (Expense) $51,632,000 +26%
Earnings Per Share, Basic -4.95 -34%
Earnings Per Share, Diluted -4.95 -34%
Cash and Cash Equivalents, at Carrying Value $101,536,000 -62%
Cash, Cash Equivalents, and Short-term Investments $1,000,000,000 -29%
Accounts Receivable, after Allowance for Credit Loss, Current $592,000
Inventory, Net $2,022,000
Other Assets, Current $3,456,000 +44%
Assets, Current $1,048,342,000 -24%
Property, Plant and Equipment, Net $14,296,000 +18%
Operating Lease, Right-of-Use Asset $40,492,000 -6.9%
Assets $1,126,257,000 -21%
Accounts Payable, Current $22,611,000 +286%
Contract with Customer, Liability, Current $1,235,000 -43%
Liabilities, Current $85,072,000 +43%
Contract with Customer, Liability, Noncurrent $3,810,000 -19%
Operating Lease, Liability, Noncurrent $42,052,000 -5.6%
Other Liabilities, Noncurrent $3,240,000 +291%
Liabilities $134,174,000 +22%
Common Stocks, Including Additional Paid in Capital $2,407,757,000 +5.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,865,000 +94%
Retained Earnings (Accumulated Deficit) $1,417,427,000 -49%
Stockholders' Equity Attributable to Parent $992,083,000 -25%
Liabilities and Equity $1,126,257,000 -21%
Common Stock, Shares Authorized 200,000,000 0%
Common Stock, Shares, Issued 95,575,000 +2.9%
Common Stock, Par or Stated Value Per Share 0.001 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102,336,000 -62%
Deferred Tax Assets, Valuation Allowance $392,031,000 +39%
Deferred Tax Assets, Gross $401,271,000 +38%
Operating Lease, Liability $48,541,000 -6.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $464,415,000 -56%
Lessee, Operating Lease, Liability, to be Paid $71,979,000 -9.4%
Property, Plant and Equipment, Gross $22,248,000 +12%
Operating Lease, Liability, Current $6,489,000 -9.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $6,999,000 +3%
Lessee, Operating Lease, Liability, to be Paid, Year One $6,795,000 -9%
Operating Lease, Weighted Average Discount Rate, Percent 0.086 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $23,438,000 -15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,209,000 +3%
Deferred Tax Assets, Operating Loss Carryforwards $201,110,000 +84%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Authorized 10,000,000 0%
Unrecognized Tax Benefits $14,752,000 +38%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,425,000 +3%
Preferred Stock, Shares Outstanding 0
Deferred Tax Assets, Net of Valuation Allowance $9,240,000 -5.2%
Share-based Payment Arrangement, Expense $91,024,000 +31%
Preferred Stock, Par or Stated Value Per Share 0.001 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY